At its March meeting, Norwegian decision forum (Beslutningsforum) handled 18 cases and approved introduction in 13.
Key decisions (selected):
- Etranacogene dezaparvovec (Hemgenix) was introduced for adults with moderate to severe haemophilia B. The forum noted it is a one-time treatment with the aim of replacing regular factor IX substitution therapy, meaning patients may avoid frequent infusions.
- The forum’s chair, Jan Frich, said Hemgenix was not introduced when discussed in November due to uncertainty about how long the effect lasts and a high price; a newly negotiated price enabled approval.
- Three non-small cell lung cancer medicines were introduced: tislelizumab (Tevimbra), osimertinib (Tagrisso) and tepotinib (Tepmetko).
- Ciltacabtagene autoleucel (Carvykti) was not introduced for relapsed/refractory multiple myeloma; the forum cited lack of cost-effectiveness at the offered price and significant budget impact, and asked Sykehusinnkjøp to resume negotiations.
Read more at https://www.nyemetoder.no/aktuelt/innforernygenterapitil-sjelden-blodersykdom/
